- Home
- EVOK vs DRMA Comparison
EVOK vs DRMA Comparison
Compare EVOK & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- DRMA
- Stock Information
- Founded
- EVOK 2007
- DRMA 2014
- Country
- EVOK United States
- DRMA United States
- Employees
- EVOK N/A
- DRMA N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- DRMA Health Care
- Exchange
- EVOK Nasdaq
- DRMA Nasdaq
- Market Cap
- EVOK 4.2M
- DRMA 4.5M
- IPO Year
- EVOK 2013
- DRMA 2021
- Fundamental
- Price
- EVOK $2.65
- DRMA $0.60
- Analyst Decision
- EVOK
- DRMA Strong Buy
- Analyst Count
- EVOK 0
- DRMA 1
- Target Price
- EVOK N/A
- DRMA $3.00
- AVG Volume (30 Days)
- EVOK 18.7K
- DRMA 94.5K
- Earning Date
- EVOK 08-12-2025
- DRMA 08-06-2025
- Dividend Yield
- EVOK N/A
- DRMA N/A
- EPS Growth
- EVOK N/A
- DRMA N/A
- EPS
- EVOK N/A
- DRMA N/A
- Revenue
- EVOK $11,594,083.00
- DRMA N/A
- Revenue This Year
- EVOK $57.82
- DRMA N/A
- Revenue Next Year
- EVOK $59.12
- DRMA N/A
- P/E Ratio
- EVOK N/A
- DRMA N/A
- Revenue Growth
- EVOK 89.89
- DRMA N/A
- 52 Week Low
- EVOK $1.94
- DRMA $0.57
- 52 Week High
- EVOK $12.32
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- EVOK 39.39
- DRMA 29.24
- Support Level
- EVOK $2.46
- DRMA $0.57
- Resistance Level
- EVOK $2.84
- DRMA $0.63
- Average True Range (ATR)
- EVOK 0.28
- DRMA 0.04
- MACD
- EVOK -0.05
- DRMA -0.01
- Stochastic Oscillator
- EVOK 15.40
- DRMA 11.55
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.